Results of markers of kidney injury in the three groups.

<p>(A) serum creatinine; (B) serum BUN; (C) serum CysC; (D) urine NAG, urine N-acetyl-β-D-glucosaminidase. Data are presented as mean±SD, n = 6, *<i>P</i> <0.05 versus Group C, Ψ<i>P</i> <0.05 versus Group S. For graphs pooled estimates for pairwise comparisons derived from Analysis of Covariance with adjustment for baseline serum creatinine at 53.61±9.53μmmol/L, serum BUN 4.31±1.34μmmol/L, serum CysC 24.35±4.2μg/L, were as follows: <b>serum creatinine;</b> 5min post CPB(T2): Group C, 64.24±12.53μmmol/L, Group U, 62.33±11.73μmmol/L. Test for overall treatment effect <i>P</i> = 0.074. 120min post CPB(T3): Group C, 86.62±11.41μmmol/L, Group U, 71.72±12.55μmmol/L. Test for overall treatment effect <i>P</i> = 0.032. <b>serum BUN;</b> 5min post CPB(T2): Group C, 5.43±1.87μmmol/L, Group U, 5.41±1.72μmmol/L. Test for overall treatment effect <i>P</i> = 0.081. 120min post CPB(T3): Group C, 7.37±1.72μmmol/L, Group U, 6.13±1.69μmmol/L. Test for overall treatment effect <i>P</i> = 0.025. <b>serum CysC;</b> 5min post CPB(T2): Group C, 30.47±4.4μg/L, Group U, 26.66±5.7μg/L. Test for overall treatment effect <i>P</i> = 0.069. 120min post CPB(T3): Group C, 40.62±6.5μg/L, Group U, 30.72±6.2μg/L. Test for overall treatment effect <i>P</i> = 0.001.